PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical studies Provisional patent application on the novel drug delivery platform which can be loaded into products such as tablets, capsules, sachets and pouches TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of pla ...

Core Insights - Avicanna Inc. reported Q3 2025 results, highlighting continued revenue growth and advancements in its biopharmaceutical strategy focused on cannabinoid-based products [1][2]. Financial Performance - Revenue for Q3 2025 reached $6.40 million, with a total of $18.88 million for the nine-month period ending September 30, 2025. Canadian revenue increased by 4%, marking two consecutive quarters of growth, while international revenue rose by approximately 6% compared to Q2 2025 [5]. - Gross profit was $3.15 million for Q3 2025, resulting in a gross margin of 49%, down from 57% in the prior year due to non-recurring costs and a Canada Post strike. The nine-month gross margin improved slightly to 52% from 50% in the previous period [5]. - The adjusted EBITDA loss for Q3 2025 was $0.79 million, a decrease from the same period in 2024, while the nine-month adjusted EBITDA loss was $0.61 million, showing improvement from $0.72 million in 2024 [5]. Commercial Advancements - Canadian commercial advancements led to record sales of 62,987 units in Q3 2025, a 39% increase compared to Q3 2024. The company had 52 commercial SKUs and 174 listings, representing 29% growth from Q3 2024 and 18% growth from Q2 2025 [5]. - The MyMedi.ca platform experienced growth due to medical affairs initiatives, and the B2B Medical unit saw a 113% increase in products sold. The Adult-Use business expanded into three new provinces and territories [5]. Intellectual Property and Collaborations - The United States Patent & Trademark Office issued patent No. US 12,343,315 B2 for a topical gel formulation containing cannabinoids, aimed at treating skin conditions such as acne and wrinkles [5]. - Avicanna's subsidiary completed the export of CBD-dominant cannabis flower to Switzerland, marking the first export of organic certified flower and expanding the Aureus portfolio in international markets [5]. New Product Launches - Avicanna LATAM SAS and Harrington Wellness launched the re+PLAY CBD wellness brand in the U.S., featuring products that utilize Avicanna's patented CBD formulations [6].

Core Insights - Avicanna Inc. reported Q2 2025 results, highlighting growth in its commercial channels and achieving positive adjusted EBITDA for the first half of 2025, indicating operational efficiency and financial discipline [2][5]. Financial Highlights - Revenue for Q2 2025 was $6.16 million, a 1% increase year-over-year, while revenue for the six-month period was $12.48 million, reflecting a 1% decrease compared to the same period in 2024 [5]. - Gross profit for Q2 was $3.13 million, with a gross margin of 51%, and for the six-month period, gross profit totaled $6.73 million with a margin of 54%, up from 47% in the prior-year periods [5]. - Adjusted EBITDA showed a loss of $0.25 million for Q2 but a gain of $0.18 million for the six-month period, marking an improvement from losses of $0.44 million and $0.42 million in the same periods of 2024 [5]. Corporate Highlights - The company expanded its product offerings, ending Q2 with 50 commercial SKUs and 147 listings, representing a 19% increase in SKUs and a 9% increase in listings from Q1 2025 [5]. - Avicanna sold 50,789 units in Q2, a 21% increase compared to the same period in 2024 [5]. - The company announced a sponsorship for a Phase II clinical study on osteoarthritis pain, which is its first placebo-controlled, blinded randomized multicenter trial [5]. - A symposium on cannabinoid-based medicine was held in June 2025, focusing on research and clinical applications, attended by key opinion leaders and healthcare providers [5]. - Avicanna received a new patent from the US Patent and Trademark Office for a topical cannabinoid composition aimed at treating skin conditions [5][6].